News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ReNeuron Reports Encouraging Signs From Parkinson’s Disease Programme
February 16, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ReNeuron Group PLC said the stem cells it is working on to find a treatment for Parkinson's disease have shown attributes that could be used to reverse the effects of the illness.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Lung cancer
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
September 15, 2026
·
3 min read
·
Tristan Manalac
Deals
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
September 15, 2026
·
2 min read
·
Gabrielle Masson
Lung cancer
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
September 14, 2026
·
4 min read
·
Gabrielle Masson
Psychedelics
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
September 14, 2026
·
3 min read
·
Heather McKenzie